Nektar Therapeutics Loss Form

Company: Nektar Therapeutics

Ticker: (NASDAQ) NKTR

Deadline

Passed

Lead Plaintiff Deadline: December 31, 2018

Every year, thousands of shareholders miss deadlines to receive settlement funds. Make sure you don’t. Sign up for case alerts.

To receive more detailed alerts provide your information below.

Request Case Alerts

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit. No spam will be sent to your email.

Allegations

(1) prior studies which attempted to pegylate IL-2 failed; (2) the extended half-life of the Company’s lead I-O candidate, NKTR-214, was unlikely to result in efficacy and created additional high-dosing safety concerns; (3) NKTR-214 was less effective than IL-2 alone; (4) the combination of NKTR-214 with nivolumab has yet to demonstrate significant positive results; and (5) as a result, Nektar’s public statements as set forth above were materially false and misleading at all relevant times.